Clinical trials: Recurrent GBM
Glioblastoma Multiforme, Gliosarcoma
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of dasatinib when combined with protracted, daily temozolomide (TMZ).
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00734864
- Testing
- enzyme-inducing anti-epileptic drugs
- Where
- United States
- Sponsor
- Annick Desjardins
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Glioblastoma
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive…
- Trial name
- NCT05540275
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Provincial People's Hospital
Recurrent Central Nervous System Neoplasm
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00619112
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Glioblastoma
AB154 Combined With AB122 for Recurrent Glioblastoma
This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. The study will be divided into two cohorts: Cohort A (safety cohort) and Cohort B (surgical patient cohort).
- Trial name
- NCT04656535
- Testing
- Zimberelimab, Domvanalimab
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Yale University
Brain and Central Nervous System Tumors
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor.
- Trial name
- NCT00027625
- Testing
- gefitinib, temozolomide
- Where
- 11 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
The purpose of this study is to evaluate the clinical benefit and safety of two different Dose-Intense temozolomide regimens（one-week on/one-week off regimen versus continuous dose-intense regimen）in patients with glioblastoma at…
- Trial name
- NCT02330991
- Testing
- Temozolomide
- Volunteers
- 204 people
- Sponsor
- Beijing Sanbo Brain Hospital
Brain and Central Nervous System Tumors
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354068
- Testing
- imatinib mesylate, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Duke University
Glioblastoma, Gliosarcoma
BIBF 1120 for Recurrent High-Grade Gliomas
BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01380782
- Testing
- BIBF 1120
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Patrick Y. Wen, MD
Glioblastoma, Gliosarcoma
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent).
- Conditions
- Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Trial name
- NCT03107780
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Navtemadlin
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
This phase I trial is studying the side effects and best dose of aflibercept when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme, gliosarcoma…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00650923
- Testing
- ziv-aflibercept, radiation therapy, temozolomide
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Glioblastoma - Category
Role of Repeat Resection in Recurrent Glioblastoma
Patients with recurrent Glioblastoma (GBM) are commonly presented to surgeons, along with the question of whether or not to re-resect the recurrence.
- Trial name
- NCT04838782
- Testing
- Repeat Surgical Management of Recurrent GBM
- Where
- Canada
- Sponsor
- University of Alberta
Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Background: The brain is separated from the rest of the blood stream by the blood-brain barrier. This is like a filter that protects the brain. But is also a challenge when medicines need to get into the brain.
- Conditions
- Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme, Giant Cell Glioblastoma, Glioma
- Trial name
- NCT03027388
- Testing
- LB-100
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioblastoma
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
It was previously shown that 18F-DOPA PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been…
- Trial name
- NCT01813877
- Testing
- FDOPA PET/CT
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
High Light and Low Light Dose PDT in Glioma
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00118222
- Testing
- porfimer sodium, adjuvant therapy, conventional surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
This is a multicenter study evaluating the safety and tolerability of increasing doses of Toca 511, a retroviral replicating vector, injected into the resection cavity of patients with Grade III or Grade IV Gliomas who have…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01470794
- Testing
- Toca 511 vector, Toca FC
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Tocagen Inc.
Malignant Glioma
G207 Followed by Radiation Therapy in Malignant Glioma
This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.
- Trial name
- NCT00157703
- Testing
- G207
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- MediGene
Glioblastoma, Grade IV Astrocytoma
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary (de novo) GB that has recurred or progressed (first or second recurrence, including this recurrence) after treatment(s) including surgery…
- Conditions
- Glioblastoma, Grade IV Astrocytoma, Glioblastoma Multiforme, Grade IV Glioma
- Trial name
- NCT02858895
- Testing
- MDNA55
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Medicenna Therapeutics, Inc.
GBM
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.
- Trial name
- NCT07274787
- Testing
- NaviFUS System, Lumason, Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Cincinnati
Recurrent Glioblastoma
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma
- Trial name
- NCT04717999
- Testing
- NKG2D CAR-T
- Volunteers
- 20 people
- Sponsor
- UWELL Biopharma